PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
The emergence of new infections in India is a growing concern
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC) is indicated to relieve redness of the eye due to minor eye irritations.
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Subscribe To Our Newsletter & Stay Updated
